- Market Realist•7 hours ago
In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market.
- Investopedia•8 hours ago
Ocrevus is expected to be a blockbuster drug for Roche, as the company faces generics challenge for its older, established cancer drugs
- Market Realist•8 hours ago
By the end of 2016, the number of Cosentyx’s new-to-brand prescriptions in the US for PsA and AS indications were higher than those of Amgen’s Enbrel, Johnson & Johnson’s Stelara, and AbbVie’s Humira.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||74.82 - 75.11|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||26.73|
|Dividend & Yield||2.75 (3.66%)|
|1y Target Est||N/A|